XNCR Xencor Inc

Price (delayed)

$27.12

Market cap

$1.61B

P/E Ratio

14.5

Dividend/share

N/A

EPS

$1.87

Enterprise value

$1.57B

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in ...

Highlights

The gross profit has soared by 163% YoY and by 19% from the previous quarter

XNCR's revenue has surged by 163% year-on-year and by 19% since the previous quarter

Xencor's debt has increased by 2.7% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: http://www.xencor.com

Peers: SGEN MGNX AMGN JNJ

Key stats

What are the main financial stats of XNCR

Market

Shares outstanding

59.54M

Market cap

$1.61B

Enterprise value

$1.57B

Valuations

Price to earnings (P/E)

14.5

Price to book (P/B)

2.11

Price to sales (P/S)

4.93

EV/EBIT

14.45

EV/EBITDA

13.46

EV/Sales

4.81

Earnings

Revenue

$326.64M

EBIT

$108.71M

EBITDA

$116.74M

Free cash flow

$5.51M

Per share

EPS

$1.87

Free cash flow per share

$0.09

Book value per share

$12.85

Revenue per share

$5.5

TBVPS

$14.16

Balance sheet

Total assets

$857.92M

Total liabilities

$94.9M

Debt

$34.89M

Equity

$763.02M

Working capital

$445.03M

Liquidity

Debt to equity

0.05

Current ratio

8.3

Quick ratio

7.84

Net debt/EBITDA

-0.37

Margins

EBITDA margin

35.7%

Gross margin

100%

Net margin

33.3%

Operating margin

26.3%

Efficiency

Return on assets

14.1%

Return on equity

15.7%

Return on invested capital

17.2%

Return on capital employed

13.6%

Return on sales

33.3%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

XNCR stock price

How has the Xencor stock price performed over time

Intraday

2.03%

1 week

17.81%

1 month

20.8%

1 year

-24.69%

YTD

-32.4%

QTD

1.65%

Financial performance

How have Xencor's revenue and profit performed over time

Revenue

$326.64M

Gross profit

$326.64M

Operating income

$85.91M

Net income

$108.71M

Gross margin

100%

Net margin

33.3%

Xencor's net margin has surged by 165% YoY and by 11% QoQ

The gross profit has soared by 163% YoY and by 19% from the previous quarter

XNCR's revenue has surged by 163% year-on-year and by 19% since the previous quarter

XNCR's operating margin has surged by 139% year-on-year and by 65% since the previous quarter

Growth

What is Xencor's growth rate over time

Valuation

What is Xencor stock price valuation

P/E

14.5

P/B

2.11

P/S

4.93

EV/EBIT

14.45

EV/EBITDA

13.46

EV/Sales

4.81

The EPS has increased by 32% QoQ

XNCR's P/B is 38% below its 5-year quarterly average of 3.4 and 27% below its last 4 quarters average of 2.9

XNCR's equity is up by 31% year-on-year and by 4% since the previous quarter

XNCR's revenue has surged by 163% year-on-year and by 19% since the previous quarter

XNCR's P/S is 78% below its 5-year quarterly average of 22.6 and 46% below its last 4 quarters average of 9.1

Efficiency

How efficient is Xencor business performance

The ROS has soared by 165% YoY and by 11% QoQ

The ROA has grown by 25% from the previous quarter

XNCR's ROE is up by 23% from the previous quarter

The ROIC has grown by 15% from the previous quarter

Dividends

What is XNCR's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for XNCR.

Financial health

How did Xencor financials performed over time

The company's current ratio rose by 40% YoY and by 38% QoQ

XNCR's quick ratio is up by 39% year-on-year and by 39% since the previous quarter

Xencor's debt is 95% lower than its equity

The debt to equity has soared by 150% YoY

XNCR's equity is up by 31% year-on-year and by 4% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.